Omeros Stock Rockets 81% After FDA Green-Lights Breakthrough TA-TMA Treatment

Omeros Corporation (OMER) experienced a spectacular market rally, surging 81.14% to close at $15.85 following a major regulatory triumph. The stock’s impressive $7.10 daily gain reflected renewed investor sentiment after trading began near $12.10, with intraday movements reaching as high as $16.50 before settling at the day’s close, significantly outpacing the previous close of $8.75. The NasdaqGS-listed biotech saw exceptional trading momentum as the market digested the clinical significance of this approval.

FDA Validates Yartemlea as Definitive TA-TMA Solution

The catalyst behind OMER’s impressive performance was the U.S. FDA’s approval of Yartemlea (narsoplimab-wuug), marking a watershed moment for transplant patients. This authorization establishes Yartemlea as the first and only approved therapeutic option for transplant-associated thrombotic microangiopathy (TA-TMA) across both adult and pediatric populations aged two years and older—a designation that underscores its unique position in an underserved market segment.

Mechanism and Clinical Advantage

Yartemlea operates by selectively targeting the MASP-2 enzyme within the lectin pathway of complement, addressing a fundamental biological mechanism underlying TA-TMA pathogenesis. The underlying clinical data demonstrated meaningful survival enhancements among treated patients, providing evidence-based validation for the therapeutic approach. This mechanism represents a novel intervention strategy for a rare but frequently fatal complication arising from stem cell transplantation procedures.

Market Implications and Commercial Timeline

The approval carries substantial commercial implications, with Yartemlea anticipated to reach market in early 2026. For OMER, this regulatory milestone opens significant revenue streams in both pediatric and adult therapeutic markets. Prior to this surge, OMER’s 52-week trading range reflected more modest valuation levels, making the current rally indicative of how markets price in newly expanded commercial opportunities and first-mover advantages in approved therapeutic categories.

The strong trading volume accompanying this announcement reflects institutional and retail investor enthusiasm regarding Omeros’ clinical and commercial prospects in the rare disease therapeutics data landscape.